Teva returns unwanted stem cell heart drug to Mesoblast – FierceBiotech
FierceBiotechTeva returns unwanted stem cell heart drug to MesoblastFierceBiotechCredit Suisse believes that drug could be worth $4.1 billion in peak annual sales, but stem cell therapies have waxed and waned in both popularity and testing results over… Continue reading
